A method for extracting and purifying AFB1, AFB2, AFG1 and AFG2
Through step-by-step extraction and hydrogenation reduction reaction, the problem of difficulty in separation and low yield of AFB1, AFB2, AFG1, AFG2 is solved, efficient separation and purification is achieved, the process is simplified, and the output and products of AFB2, AFG2 are improved. purity.
Patent Information
- Application Number
- CN202211271393.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-10-21
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2042-10-21
AI Technical Summary
The prior art is difficult to effectively separate and increase the yield of AFB1, AFB2, AFG1, and AFG2, resulting in cumbersome extraction process and low product purity.
The step-by-step extraction method includes primary separation and hydrogenation reduction reaction, and isolates and purifies through liquid chromatography and gradient elution procedures. The specific steps include toxin extraction, primary separation, preparation of AFB1 and AFG1, preparation of AFB2 and AFG2, using Ethyl acetate-dichloromethane and toluene-(ethyl acetate-methanol-acetic acid) were eluted as mobile phases, and combined with hydrogenation reduction reaction, the yield of AFB2 and AFG2 was increased.
Complete separation of AFB1, AFB2, AFG1, and AFG2 is achieved, the yield of AFB2 and AFG2 is improved, the extraction and separation steps are simplified, and the production efficiency and product purity are improved.
Smart Images

Figure CN115873009B_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the technical field of extraction and purification of biological toxins, and more specifically, to a method for extracting and purifying AFB1, AFB2, AFG1, and AFG2. Background Art
[0002] Aflatoxins (AFT) are difuranoid toxins produced by certain strains of Aspergillus flavus and Aspergillus parasiticus. They are extremely toxic and carcinogenic mycotoxins. Due to the stable physical and chemical properties of aflatoxins, they can be transferred between organisms through the food chain, seriously threatening human health and causing huge economic losses to agricultural and sideline products, thus attracting widespread attention.
[0003] In recent years, the research on AFT toxicology has become a hot topic in the field of mycotoxins, which requires a large amount of high-purity AFT to meet the needs of toxicological research. There are about 20 derivatives of AFT, which are named B1 (AFB1), B2 (AFB2), G1 (AFG1), G2 (AFG2), M1, M2, P1, R1, GM and toxic alcohol according to their fluorescence color, RF value and different structures under long-wave ultraviolet light. Among them, AFB1, AFB2, AFG1 and AFG2 are widely studied because of their high toxicity.
[0004] At present, AFB1, AFB2, AFG1, and AFG2 are mainly extracted and purified from artificially inoculated culture media. The yields of AFB1 and AFG1 are relatively high, while the yields of AFB2 and AFG2 are relatively low. In addition, due to the similar properties of AFB1, AFB2, AFG1, and AFG2, it is difficult to separate them completely, resulting in a cumbersome and complicated extraction process. Summary of the invention
[0005] In order to solve the above technical problems, the present application provides a method for extracting and purifying AFB1, AFB2, AFG1, and AFG2, which can not only completely separate AFB1, AFB2, AFG1, and AFG2, but also increase the yield of AFB2 and AFG2.
[0006] In the first aspect, the present application provides a method for extracting and purifying AFB1, AFB2, AFG1, and AFG2, using the following technical solution:
[0007] A method for extracting and purifying AFB1, AFB2, AFG1, and AFG2 comprises the following steps:
[0008] Toxin extraction: adding an extractant to the toxin-producing culture medium containing AFB1, AFB2, AFG1, and AFG2, and after extraction, obtaining a crude extract containing AFB1 / AFG1 / AFB2 / AFG2;
[0009] Primary separation: using preparative liquid chromatography, eluting the crude extract with ethyl acetate-dichloromethane, and collecting fractions containing AFB1 / AFG1 and fractions containing AFB1 / AFG1 / AFB2 / AFG2 respectively;
[0010] Preparation of AFB1 and AFG1: using preparative liquid chromatography, using toluene-(ethyl acetate-methanol-acetic acid) to elute the fraction containing AFB1 / AFG1, and collecting the fraction containing AFB1 and the fraction containing AFG1 respectively; then purifying the fraction containing AFB1 and the fraction containing AFG1 respectively to obtain AFB1 and AFG1;
[0011] Preparation of AFB2 and AFG2: subjecting the fraction containing AFB1 / AFG1 / AFB2 / AFG2 to hydrogenation reduction reaction to obtain a sample containing AFB2 / AFG2; using preparative liquid chromatography, using toluene-(ethyl acetate-methanol-acetic acid) to elute the sample containing AFB2 / AFG2, and collecting the fraction containing AFB2 and the fraction containing AFG2 respectively; then purifying the fraction containing AFB2 and the fraction containing AFG2 respectively to obtain AFB2 and AFG2.
[0012] By adopting the above technical scheme, the present application adopts a step-by-step extraction method, and extracts AFB1, AFB2, AFG1, and AFG2 in the toxin-producing culture medium to obtain an extract containing AFB1 / AFG1 / AFB2 / AFG2; in the initial separation, ethyl acetate-dichloromethane is used for elution to obtain a fraction containing AFB1 / AFG1, and after continuing to elute for a certain period of time, AFB2 / AFG2 can be eluted, and the remaining fraction contains AFB1, AFB2, AFG1, and AFG2 at the same time, and then the fraction containing AFB1 / AFG1 and the fraction containing AFB1 / AFG1 / AFB2 / AFG2 are separated and extracted respectively. By using toluene-(ethyl acetate-methanol-acetic acid) to elute the fraction containing AFB1 / AFG1, a fraction containing AFB1 and a fraction containing AFG1 can be obtained.
[0013] Since AFB1, AFB2, AFG1, and AFG2 have similar properties, after separating the fraction containing AFB1 / AFG1, there will still be a mixture of AFB1, AFB2, AFG1, and AFG2 in the system, resulting in a cumbersome separation and extraction process, low product purity, and low yields of AFB2 and AFG2. However, the present application converts AFB1 and AFG1 into AFB2 and AFG2 after hydrogenation reduction treatment of the fraction containing AFB1 / AFG1 / AFB2 / AFG2 obtained by preliminary separation. At this time, the problem of the difficulty in separating AFB1 and AFG1 from AFB2 and AFG2 is solved, and the yield of AFB2 and AFG2 can be increased. In addition, there are fewer extraction and separation steps, which can effectively improve production efficiency.
[0014] Optionally, in the step of preparing AFB2 and AFG2, the hydrogenation reduction reaction comprises the following steps:
[0015] The fraction containing AFB1 / AFG1 / AFB2 / AFG2 is concentrated to dryness to obtain a sample containing AFB1 / AFG1 / AFB2 / AFG2;
[0016] Add 1,4-dioxane to the sample containing AFB1 / AFG1 / AFB2 / AFG2, stir and dissolve, and obtain a mixed solution;
[0017] A catalyst was added to the mixed solution, and then hydrogen was introduced, and the mixture was stirred and reacted at a temperature of 55-65° C. for 15-20 h to obtain a sample containing AFB2 / AFG2.
[0018] Optionally, the weight ratio of the sample containing AFB1 / AFG1 / AFB2 / AFG2 to 1,4-dioxane is 1:15-25.
[0019] Optionally, the weight ratio of the sample containing AFB1 / AFG1 / AFB2 / AFG2 to the catalyst is 10:0.8-1.2.
[0020] Optionally, the catalyst is a Pd-CaCO3 catalyst.
[0021] Optionally, in the preliminary separation, ethyl acetate is used as mobile phase A, dichloromethane is used as mobile phase B, and a gradient elution program is used for extraction and separation;
[0022] The gradient elution program is: 0 min, 20% A and 80% B; 5 min, 20% A and 80% B; 10 min, 30% A and 70% B; 20 min, 30% A and 70% B; 30 min, 40% A and 60% B;
[0023] The collection time of the fractions containing AFB1 / AFG1 was 16.1-21.7 min, and the collection time of the fractions containing AFB1 / AFG1 / AFB2 / AFG2 was 21.7-24.6 min.
[0024] By adopting the above technical solution and the above elution procedure for elution, the elution time is short and the separation efficiency is high.
[0025] Optionally, in the step of preparing AFB1 and AFG1, toluene is used as mobile phase A, ethyl acetate-methanol-acetic acid is used as mobile phase B, and a gradient elution program is used for extraction and separation;
[0026] The gradient elution program is: 0 min, 5% A and 95% B; 5 min, 5% A and 95% B; 10 min, 10% A and 90% B; 20 min, 10% A and 90% B; 30 min, 15% A and 85% B;
[0027] The collection time of the fractions containing AFB1 was 17.1-20.2 min, and the collection time of the fractions containing AFG1 was 21.3-23.5 min.
[0028] Optionally, in the step of preparing AFB2 and AFG2, toluene is used as mobile phase A, ethyl acetate-methanol-acetic acid is used as mobile phase B, and a gradient elution program is used for extraction and separation;
[0029] The gradient elution program is: 0 min, 5% A and 95% B; 5 min, 5% A and 95% B; 10 min, 10% A and 90% B; 20 min, 10% A and 90% B; 30 min, 15% A and 85% B;
[0030] The collection time of the fractions containing AFB2 was 18.1-20.2 min, and the collection time of the fractions containing AFG2 was 22.3-23.8 min.
[0031] Optionally, the volume ratio of ethyl acetate, methanol and acetic acid is 3:1:1.
[0032] Optionally, in the toxin extraction step, the extractant is dichloromethane.
[0033] Optionally, the toxin-producing culture medium is wheat culture medium or rice culture medium.
[0034] Optionally, in the step of preparing AFB1 and AFG1, the purification process comprises the following steps:
[0035] After the fraction containing AFB1 is concentrated to dryness, chloroform is added and stirred to dissolve, and then n-hexane is slowly added until no solid is precipitated. After stirring evenly, the mixture is filtered and the filter cake is washed and dried to obtain AFB1.
[0036] In summary, this application has the following beneficial effects:
[0037] Since AFB1, AFB2, AFG1, and AFG2 have similar properties, after separating the fraction containing AFB1 / AFG1, there will still be a mixture of AFB1, AFB2, AFG1, and AFG2 in the system, resulting in a cumbersome separation and extraction process, low product purity, and low yields of AFB2 and AFG2. However, the present application converts AFB1 and AFG1 into AFB2 and AFG2 after hydrogenation reduction treatment of the fraction containing AFB1 / AFG1 / AFB2 / AFG2 obtained by preliminary separation. At this time, the problem of the difficulty in separating AFB1 and AFG1 from AFB2 and AFG2 is solved, and the yield of AFB2 and AFG2 can be increased. In addition, there are fewer extraction and separation steps, which can effectively improve production efficiency. BRIEF DESCRIPTION OF THE DRAWINGS
[0038] Figure 1 It is the ultra-high pressure liquid chromatogram of Example 1 of the present application, wherein (a) is a crude extract containing AFB1 / AFG1 / AFB2 / AFG2; (b) is an AFT mixed standard (composed of standard substances AFB1, AFG1, AFB2, and AFG2); (c) is purified crystal B1; (d) is purified crystal B2; (e) is purified crystal G1; and (f) is purified crystal G2.
[0039] Figure 2 This is the mass spectrum of AFB1 in Example 1 of the present application.
[0040] Figure 3 This is the mass spectrum of AFB2 in Example 1 of the present application.
[0041] Figure 4 This is the mass spectrum of AFG1 in Example 1 of the present application.
[0042] Figure 5 This is the mass spectrum of AFG2 in Example 1 of the present application. DETAILED DESCRIPTION
[0043] The present application is further described below in conjunction with the accompanying drawings and embodiments.
[0044] Example
[0045] Unless otherwise specified, the raw materials in the examples can be obtained from commercial sources. Among them, the toxin-producing strain is Aspergillus parasiticus, purchased from China General Microorganism Collection Center, numbered CGMCC36155.
[0046] Example 1
[0047] A method for extracting and purifying AFB1, AFB2, AFG1, and AFG2 comprises the following steps:
[0048] 1. Bacteria activation
[0049] A ring of mycelium of the toxin-producing strain was picked from the preserved slant, inoculated in the middle of a potato culture medium (PDA), and then placed in a constant temperature box at 28°C for 3 days to obtain an activated bacterial cake.
[0050] 2. Preparation of Seed Solution
[0051] Add 100 mL of PD liquid culture medium into a 250 mL Erlenmeyer flask, then inoculate 2 bacterial cakes (5 mm in diameter and 2 mm in thickness) into the flask, and culture under shaking conditions of 25°C and 150 r / min for 5 days to obtain seed solution.
[0052] 3. Preparation of Toxigenic Culture Medium
[0053] (1) Grind wheat into wheat flour with a particle size of 1-1.2 mm, take 80 g of wheat flour and add it into a culture box, add 80 mL of purified water into the culture box and soak it for 1 hour; then place the culture box in a sterilizer and sterilize it at high temperature and high pressure to obtain a wheat culture medium.
[0054] (2) Stir the agglomerated wheat culture medium with a sterilization rod to make it fluffy, and then sterilize it by ultraviolet irradiation for 20 minutes.
[0055] (3) Using a pipette, take 1000 μL of seed solution and inoculate it into the fluffy wheat culture medium; culture the inoculated wheat culture medium at 28° C. for 21 days to obtain a toxin-producing culture medium.
[0056] 4. Extraction of toxins
[0057] Pour 5000 g of toxin-producing culture medium into a stainless steel stirring barrel, add dichloromethane (DCM) 2.5 times the weight of the toxin-producing culture medium, stir evenly, seal the stainless steel barrel, soak the toxin-producing culture medium in dichloromethane for 24 hours, filter, collect the filtrate to obtain a crude extract.
[0058] 5. Separation and purification
[0059] (1) Preparation of samples containing AFB1 / AFG1 and samples containing AFB1 / AFG1 / AFB2 / AFG2:
[0060] ① After the crude extract is concentrated to dryness, 30 g of sample is obtained; the sample is ultrasonically re-dissolved with 30 mL of dichloromethane to obtain a re-dissolved solution.
[0061] ② The reconstituted solution was separated and extracted by preparative liquid chromatography, and the chromatographic conditions were as follows:
[0062] Chromatographic column 330g; flow rate 20mL / min; detection wavelength 365nm; injection volume 30mL;
[0063] The mobile phase includes mobile phase A and mobile phase B, mobile phase A is ethyl acetate, and mobile phase B is dichloromethane;
[0064] The gradient elution program was: 0 min, 20% A and 80% B; 5 min, 20% A and 80% B; 10 min, 30% A and 70% B; 20 min, 30% A and 70% B; 30 min, 40% A and 60% B; the total running time was 30 min; the collection time of the fractions containing AFB1 / AFG1 was 16.1-21.7 min, and the collection time of the fractions containing AFB1 / AFG1 / AFB2 / AFG2 was 21.7-24.6 min.
[0065] ③ The fraction containing AFB1 / AFG1 was concentrated to dryness by rotary evaporation at 50°C to obtain 4.1 g of sample containing AFB1 / AFG1. The fraction containing AFB1 / AFG1 / AFB2 / AFG2 was concentrated to dryness to obtain 2.5 g of sample containing AFB1 / AFG1 / AFB2 / AFG2.
[0066] (2) Preparation of AFB1 and AFG1 samples:
[0067] ① 4.1 g of the sample containing AFB1 / AFG1 was re-dissolved by ultrasonication in 10 mL of dichloromethane to obtain a re-dissolved solution.
[0068] ② The reconstituted solution was separated and extracted by preparative liquid chromatography, and the chromatographic conditions were as follows:
[0069] Chromatographic column 220g; flow rate 20mL / min; detection wavelength 365nm; injection volume 10mL;
[0070] The mobile phase includes mobile phase A and mobile phase B, mobile phase A is toluene, and mobile phase B is composed of ethyl acetate, methanol and acetic acid in a volume ratio of 3:1:1;
[0071] The gradient elution program was: 0 min, 5% A and 95% B; 5 min, 5% A and 95% B; 10 min, 10% A and 90% B; 20 min, 10% A and 90% B; 30 min, 15% A and 85% B; the total running time was 30 min; the collection time of the fractions containing AFB1 was 17.1-20.2 min, and the collection time of the fractions containing AFG1 was 21.3-23.5 min.
[0072] ③ The fraction containing AFB1 was concentrated to dryness by rotary evaporation at 50°C to obtain 1.8 g of AFB1 sample. The fraction containing AFG1 was concentrated to dryness to obtain 0.8 g of AFG1 sample.
[0073] ④ Take the AFB1 sample obtained above, add 10 mL of chloroform and stir to dissolve, slowly add 5 mL of n-hexane until no solid precipitates, stir evenly and filter, wash the filter cake with 6 mL of a mixed reagent of petroleum ether / ethyl acetate (volume ratio of 1:2), and after drying, obtain 1150 mg of crystalline B1.
[0074] ⑤ Take the AFG1 sample obtained above, add 8 mL of chloroform and stir to dissolve, slowly add 5 mL of n-hexane until no solid precipitates, stir evenly and filter, wash the filter cake with 4 mL of a mixed reagent of petroleum ether: ethyl acetate (volume ratio of 1:2), and after drying, obtain 450 mg of crystalline G1.
[0075] (3) Preparation of samples containing AFB2 and AFG2:
[0076] Transfer 2.5 g of the sample containing AFB1 / AFG1 / AFB2 / AFG2 obtained in step (1) to a 100 mL single-mouth bottle, add 50 mL of 1,4-dioxane and stir to dissolve, and obtain a mixed solution; then weigh 0.25 g of Pd-CaCO3 catalyst and add it to the mixed solution. After the addition is completed, connect the tee and hydrogen, and replace the hydrogen three times with a water pump to keep the mixed solution connected with the hydrogen; stir the reaction at a temperature of 60°C for 16 hours, and after the reaction is completed, turn off the hydrogen and stop the reaction; filter the obtained reaction solution through diatomaceous earth to obtain a filter cake, then wash the filter cake with 20 mL of dichloromethane, and combine the filtrate; concentrate the filtrate to dryness to obtain 2.5 g of the sample containing AFB2 / AFG2.
[0077] (4) Preparation of AFB2 and AFG2 samples:
[0078] ① The 2.5 g sample containing AFB2 / AFG2 prepared in step (3) was ultrasonically re-dissolved with 8 mL of dichloromethane to obtain a re-dissolved solution.
[0079] ② The reconstituted solution was separated and extracted by preparative liquid chromatography, and the chromatographic conditions were as follows:
[0080] Chromatographic column 120g; flow rate 20mL / min; detection wavelength 365nm; injection volume 8mL;
[0081] The mobile phase includes mobile phase A and mobile phase B, mobile phase A is toluene, and mobile phase B is composed of ethyl acetate, methanol and acetic acid in a volume ratio of 3:1:1;
[0082] The gradient elution program was: 0 min, 5% A and 95% B; 5 min, 5% A and 95% B; 10 min, 10% A and 90% B; 20 min, 10% A and 90% B; 30 min, 15% A and 85% B; the total running time was 30 min; the collection time of the fractions containing AFB2 was 18.1-20.2 min, and the collection time of the fractions containing AFG2 was 22.3-23.8 min.
[0083] ③ The fraction containing AFB2 was concentrated to dryness by rotary evaporation at 50°C to obtain 0.7 g of AFB2 sample. The fraction containing AFG2 was concentrated to dryness to obtain 0.5 g of AFG2 sample.
[0084] ④ Take the AFB2 sample obtained above, add 8 mL of chloroform and stir to dissolve, slowly add 4 mL of n-hexane until no solid precipitates, stir evenly and filter, wash the filter cake with 4 mL of a mixed reagent of petroleum ether / ethyl acetate (volume ratio of 1:2), and after drying, obtain 380 mg of crystalline B2.
[0085] ⑤ Take the AFG2 sample obtained above, add 7 mL of chloroform and stir to dissolve, slowly add 3 mL of n-hexane until no solid precipitates, stir evenly and filter, wash the filter cake with 4 mL of a mixed reagent of petroleum ether: ethyl acetate (volume ratio of 1:2), and after drying, obtain 260 mg of crystalline G2.
[0086] Crystal B1, crystal G1, crystal B2, and crystal G2 were analyzed by ultra-high pressure liquid chromatography. Figure 1 As shown, (a) is the crude extract containing AFB1 / AFG1 / AFB2 / AFG2; b is the AFT standard substance; c is the purified AFB1; d is the purified AFB2; e is the purified AFG1; f is the purified AFG2; according to Figure 1 It can be seen that the peak times of c, d, e, and f are the same as the peak times of the peaks of the AFT mixed standard (a), indicating that the crystal B1 prepared in the example is AFB1, the crystal G1 is AFG1, the crystal B2 is AFB2, and the crystal G2 is AFG2.
[0087] Figure 2 is the mass spectrum of AFB1. Figure 3 is the mass spectrum of AFB2. Figure 3 is the mass spectrum of AFG1, Figure 4 is the mass spectrum of AFG2; according to Figure 2-5 The full scan spectrum shows that Figure 2-5 The mass spectrum has few impurity peaks, indicating that AFB1, AFB2, AFG1, and AFG2 extracted in the embodiment of the present application have high purity.
[0088] In this example, 1150 mg AFB1, 450 mg AFG1, 380 mg AFB2 and 260 mg AFG2 were extracted from 5000 g of toxin-producing culture medium, indicating that the product yield obtained by the method of the present application is high. In addition, according to the extraction method of Example 1 of the present application, it can be seen that the extraction method of the present application is simple, has few extraction steps, and has high extraction efficiency, and is suitable for industrial large-scale production.
[0089] This specific embodiment is merely an explanation of the present application and is not a limitation of the present application. After reading this specification, those skilled in the art may make modifications to the present embodiment without any creative contribution as needed, but such modifications are protected by the patent law as long as they are within the scope of the claims of the present application.
Claims
1. A method for extracting and purifying AFB1, AFB2, AFG1, and AFG2, characterized in that: The steps include: Toxin extraction: adding an extractant to the toxin-producing culture medium containing AFB1, AFB2, AFG1, and AFG2, and after extraction, obtaining a crude extract containing AFB1 / AFG1 / AFB2 / AFG2; In the toxin extraction step, the extractant is dichloromethane; Primary separation: using preparative liquid chromatography, eluting the crude extract with ethyl acetate-dichloromethane, and collecting fractions containing AFB1 / AFG1 and fractions containing AFB1 / AFG1 / AFB2 / AFG2 respectively; Preparation of AFB1 and AFG1: using preparative liquid chromatography, using toluene-(ethyl acetate-methanol-acetic acid) to elute the fraction containing AFB1 / AFG1, and collecting the fraction containing AFB1 and the fraction containing AFG1 respectively; then purifying the fraction containing AFB1 and the fraction containing AFG1 respectively to obtain AFB1 and AFG1; Preparation of AFB2 and AFG2: subjecting the fraction containing AFB1 / AFG1 / AFB2 / AFG2 to hydrogenation reduction reaction to obtain a sample containing AFB2 / AFG2; using preparative liquid chromatography, using toluene-(ethyl acetate-methanol-acetic acid) to elute the sample containing AFB2 / AFG2, and collecting the fraction containing AFB2 and the fraction containing AFG2 respectively; then purifying the fraction containing AFB2 and the fraction containing AFG2 respectively to obtain AFB2 and AFG2.
2. A method for extracting and purifying AFB1, AFB2, AFG1, and AFG2 according to claim 1, characterized in that: In the step of preparing AFB2 and AFG2, the hydrogenation reduction reaction comprises the following steps: The fraction containing AFB1 / AFG1 / AFB2 / AFG2 is concentrated to dryness to obtain a sample containing AFB1 / AFG1 / AFB2 / AFG2; Add 1,4-dioxane to the sample containing AFB1 / AFG1 / AFB2 / AFG2, stir and dissolve, and obtain a mixed solution; A catalyst was added to the mixed solution, and then hydrogen was introduced, and the mixture was stirred and reacted at a temperature of 55-65° C. for 15-20 h to obtain a sample containing AFB2 / AFG2.
3. A method for extracting and purifying AFB1, AFB2, AFG1, and AFG2 according to claim 2, characterized in that: The weight ratio of the sample containing AFB1 / AFG1 / AFB2 / AFG2 to 1,4-dioxane is 1:15-25.
4. A method for extracting and purifying AFB1, AFB2, AFG1, and AFG2 according to claim 2, characterized in that: The weight ratio of the sample containing AFB1 / AFG1 / AFB2 / AFG2 to the catalyst is 10:0.8-1.
2.
5. The method for extracting and purifying AFB1, AFB2, AFG1 and AFG2 according to claim 1, characterized in that: In the initial separation, ethyl acetate is used as mobile phase A, dichloromethane is used as mobile phase B, and a gradient elution program is used for extraction and separation; The gradient elution program is: 0 min, 20% A and 80% B; 5 min, 20% A and 80% B; 10 min, 30% A and 70% B; 20 min, 30% A and 70% B; 30 min, 40% A and 60% B; The collection time of the fractions containing AFB1 / AFG1 was 16.1-21.7 min, and the collection time of the fractions containing AFB1 / AFG1 / AFB2 / AFG2 was 21.7-24.6 min.
6. The method for extracting and purifying AFB1, AFB2, AFG1 and AFG2 according to claim 1, characterized in that: In the step of preparing AFB1 and AFG1, toluene is used as mobile phase A, ethyl acetate-methanol-acetic acid is used as mobile phase B, and a gradient elution program is used for extraction and separation; The gradient elution program is: 0 min, 5% A and 95% B; 5 min, 5% A and 95% B; 10 min, 10% A and 90% B; 20 min, 10% A and 90% B; 30 min, 15% A and 85% B; The collection time of the fractions containing AFB1 was 17.1-20.2 min, and the collection time of the fractions containing AFG1 was 21.3-23.5 min.
7. The method for extracting and purifying AFB1, AFB2, AFG1 and AFG2 according to claim 1, characterized in that: In the step of preparing AFB2 and AFG2, toluene is used as mobile phase A, ethyl acetate-methanol-acetic acid is used as mobile phase B, and a gradient elution program is used for extraction and separation; The gradient elution program is: 0 min, 5% A and 95% B; 5 min, 5% A and 95% B; 10 min, 10% A and 90% B; 20 min, 10% A and 90% B; 30 min, 15% A and 85% B; The collection time of the fractions containing AFB2 was 18.1-20.2 min, and the collection time of the fractions containing AFG2 was 22.3-23.8 min.
8. The method for extracting and purifying AFB1, AFB2, AFG1 and AFG2 according to claim 1, characterized in that: The volume ratio of ethyl acetate, methanol and acetic acid is 3:1:
1.
9. The method for extracting and purifying AFB1, AFB2, AFG1 and AFG2 according to claim 1, characterized in that: In the step of preparing AFB1 and AFG1, the purification process comprises the following steps: After the fraction containing AFB1 is concentrated to dryness, chloroform is added and stirred to dissolve, and then n-hexane is slowly added until no solid is precipitated. After stirring evenly, the mixture is filtered and the filter cake is washed and dried to obtain AFB1.
